118 results about "Liver lipid" patented technology

The invention discloses a composition with an auxiliary protection effect on an alcoholic liver injury and a preparation method of the composition. The composition with the auxiliary protective effect on the alcoholic liver injury is mainly prepared from the following raw materials in parts by weight: 57.5-172.5 parts of kudzuvine root extract, 22.5-67.5 parts of semen hoveniae extract, 35-105 parts of salvia miltiorrhiza extract, 18-57 parts of turmeric extract and 7.5-22.5 parts of ammonium glycyrrhetate. The raw materials respectively have anti-lipid peroxidation effect and protective effect on the liver. Functional tests show that the composition with the auxiliary protection effect on the alcoholic liver injury has better liver protection effect compared with the same dose of single kudzuvine root extract preparation and single semen hoveniae extract preparation, and liver fatty degeneration and liver lipid peroxidation which are caused by the alcoholic liver injury can be obviously alleviated. The composition with the auxiliary protection effect is prepared by adopting a scientific and reasonable production process, is definite in functions, controllable in quality and safe to take and is applicable to a large group of people suffering from the alcoholic liver injury.

The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

Belonging to the field of medical technologies, the present invention discloses application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid. Specifically, blood lipid refers to total cholesterol and low density lipoprotein in serum, and liver lipid refers to total cholesterol in liver. Toxicity tests show that aloe-emodin has no obvious toxic and side effect. Pharmacodynamic tests of aloe-emodin show that aloe-emodin can significantly reduce the total cholesterol and low density lipoprotein in hyperlipidemia animal model serum, and has obvious blood lipid reducing effect. At the same time, aloe-emodin can also significantly reduce the total cholesterol content of a hyperlipidemia animal model liver, and has obvious liver lipid reducing effect. Therefore, the invention puts forward the application of aloe-emodin in reduction of blood lipid and liver lipid, aloe-emodin has the characteristics of significant lipid reducing effect, low toxicity, no irritation, low price, and convenient production, transportation, storage and taking, and can have broad application prospects as a blood lipid and liver lipid reducing drug.

Niacin prevents and/or reverses the development of experimental hepatic steatosis, deposition of triglycerides in liver and serum of individuals, deposition of total cholesterol in liver and serum in individuals, and inhibit liver lipid peroxidation and oxidative stress in individuals at risk of developing fatty liver disease or NAFLD. In cultured human hepatocytes, niacin inhibits alcohol-induced fat accumulation.

The invention relates to an application of nicotinamide riboside in preparing drugs for treating non-alcoholic steatohepatitis. According to the application, a non-alcoholic steatohepatitis animal model is adopted to prove that the nicotinamide riboside is capable of reducing the liver lipid content, the liver inflammations and the liver fibrosis degree of the animal model and prompt that the nicotinamide riboside can be applied to preparing the drugs for treating the non-alcoholic steatohepatitis. The application of the nicotinamide riboside is expanded, a new way is provided for treating the non-alcoholic steatohepatitis, and therefore, the non-alcoholic steatohepatitis can be prevented and prognosed favorably.

The invention discloses yacon tea for clearing liver and detoxifying and a preparation method thereof. The yacon tea consists of the following raw materials by weight: 80-120 parts of yacon, 2-4 parts of gallnut pollen, 5-8 parts of tremella powder, 10-20 parts of emblic leafflower fruit juice, 15-20 parts of bayberry juice, 6-8 parts of Chinese artichoke, 8-10 parts of lily petals, 8-10 parts of Nymphoides peltatum flowers, 10-12 parts of barley powder, 2-4 parts of Kangxian flowers, 1-3 parts of bellflower, 2-3 parts of pseudo-ginseng, 1-2 parts of stellate cladonia fruticose thallus, 2-3 parts of Broussonetia papyrifera, 2-3 parts of hovenia dulcis thunb, and a proper amount of black garlic nutrient solution. The yacon tea for clearing liver and detoxifying combines drink and food as one, is sanitary and convenient, has strong fragrant moist taste, rich and balanced nutrition and the functions of nourishing yin and spleen, protecting liver, strengthening stomach, cooling blood, detoxifying, soothing the nerves, eliminating vexation, promoting digestion and absorption, enhancing liver lipid metabolism, improving liver detoxification function and nourishing the five internal organs; therefore, the yacon tea is beneficial to the human body health.

The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate.

The invention discloses application of a baicalein extract in preparation of a medicament for controlling hyperlipidemic fatty liver. The baicalein extract is proved to have effect of preventing the hyperlipidemic fatty liver in pharmacological experiments, and is particularly used for reducing the liver weight and the liver coefficient of rats and reducing the content of the blood fat and liver lipid.

The present invention discloses application of miRNA-378 in treatment of fatty liver. In particular, the miRNA-378 in liver is confirmed to be an insulin signal pathway regulating core element. When the miR-378 is overexpressed in mouse liver, mouse lipid metabolism steady state is enhanced, and is mainly shown as decreased liver TG content, wherein the miR-378 can perform functions through inhibition of insulin signal pathway key protein p110 alpha, so that inhibition of the expression of the p110 alpha by the overexpression of the miR-378 in the liver can be a new therapeutic strategy for liver lipid accumulation.

The present invention relates to halobios, specifically two kinds of acaleph proteins capable of antioxidant activity, its separation step is: after grinding acaleph and breaking cell, filling into phosphate buffer solution, marinating 0.5 to 2h at 2 to 6DEG C; centrifuging 10 to 30min with rotate speed 10000 to 20000rpm, taking the supernatant; marinating with phosphate buffer solution again, centrifuging 10 to 30min with rotate speed 10000 to 20000rpm; combining the two times centrifugal supernatant; separating the combined supernatant by gel filtration chromatography to obtain two kinds of acaleph proteins; they can inhibit superoxide anion radical( O2-.), hydroxyl radical (. OH) generating, prevent red blood cell hemolysis due to hydroxide peroxidation and liver lipid peroxidation; belonging to natural antioxidants, high antioxidant activity, no poison to human and livestock; the present invention uses abundant acaleph halobios resource at the same time, for low-value of the resources to provide a new path for high value development.

The invention discloses application of E3 ubiquitin ligase RNF14 in preparation of a drug for treating fatty liver and related diseases, and belongs to a new use of the RNF14. In the present invention, a L02 cell line overexpressed by human normal liver cell line L02 and the RNF14 is used as an experimental object, and the gene function of the RNF14 is studied by a fatty liver cell model co-induced by palmitic acid (PA) and oleic acid (OA). The study finds that RNF14 overexpression can significantly improve lipid accumulation in liver cells, indicating that the RNF14 can protect the liver cells from fatty degeneration, and the RNF14 plays a protective role in liver lipid metabolic diseases. Since the RNF14 is an endogenous protein kin the body, the RNF14 is highly safe as the drug.

The invention provides application of cistanche total glycosides and echinacoside in preparation of medicines for preventing and treating alcoholic liver injury with intestinal injury and regulating intestinal flora. Pharmacological experiment results show that in an alcoholic liver injury mouse model, the cistanche total glycosides and echinacoside can relieve mouse liver tissue morphological injury, reduce mouse liver lipid deposition, reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse liver, relieve oxidative injury of mouse liver, and reduce damage of harmful substances such as endotoxin and the like to liver; and meanwhile, the mouse small intestine tissue form damage can be relieved, the intestinal wall villus integrity is improved, and the intestinal flora disorder is regulated. Therefore, the invention has the prospect of being developed into a medicine capable of simultaneously protecting the alcoholic liver injury and the alcoholic intestinal injury, and has important clinical significance and commercial value.

The invention relates to a functional beverage. The functional beverage is prepared by mixing fruit juice, taurine, lysine, phosphatide, egg fat, octadecanol, myo-inositol, vitamin B1, vitamin B2, vitamin B6, vitamin B12, pantothenic acid, glucose and water. According to the functional beverage disclosed by the invention, various functional compositions are scientifically merged into the functional beverage, are matched each other, and are in synergistic reaction, so that the metabolism of human bodies can be promoted, the absorption and the decomposition of sugar contents can be promoted, a large number of energy substances are rapidly complemented, the functions of a nervous system are regulated, and the functional beverage has the functions of refreshing, restoring consciousness, complementing physical strength, improving organism endurance, increasing a basal metabolism rate, improving the metabolism of serum lipids, preventing arteriosclerosis, and improving the metabolism of liver lipid; besides, the beverage does not contain caffeine and excessive electrolytes, and when the functional beverage is drunk, damage of excessive caffeine and electrolytes to human bodies can be avoided.

The invention relates to application of great burdock root polysaccharide in preparation of a drug for treating non-alcoholic fatty liver disease (NAFLD). The great burdock root polysaccharide provided by the invention is prepared from great burdock roots, and is prepared by carrying out enzyme inactivation, extraction, filtration, suction filtration, centrifugation, ethanol precipitation, macroporous resin decolorization, trichloroacetic acid deproteinization and the like; and the great burdock root polysaccharide has an average molecular weight of 3000-5000 Da. According to the application of the great burdock root polysaccharide in the preparation of the drug for treating the NAFLD, NAFLD mouse models are established through induction by high fat diet (HFD), and are used for study on activity of the burdock root polysaccharide in NAFLD treatment; and it is found that the great burdock root polysaccharide is capable of significantly reducing liver weight and liver index so as to reduce accumulation of liver lipid, alleviate liver damage and regulate inflammatory factors so as to achieve positive therapeutic effects on the NAFLD.

The invention relates to the field of environmental toxicology models, in particular to a method for evaluating the influence of ionic liquid on lipid metabolism by using zebra fish. According to theinvention, zebra fish is used as an experimental object; and after acute exposure of the zebra fish in an ionic liquid with a certain concentration, related hormones influencing liver metabolism, physiological and biochemical indexes related to liver metabolism and expression of liver lipid metabolism related genes are determined, and histological slices of the liver are observed. By analyzing thechange of the indexes of the exposed zebra fish, the influence of the ionic liquid on the liver lipid metabolism toxicity is comprehensively and accurately evaluated. Thus, a basis is provided for formulating aquatic ecological environment pollutant standards.

Two kinds of antioxidizing protein for suppressing the generation of superoxide anion free radical and preventing the superoxidizing of red cells and liver lipid are prepared from medusa through shearing off, breaking cells, immersing in phosphoric acid as buffering solution and centrifugal separation to obtain supernatant twice, collecting the supernatant and gel chromatography to obtain the target products.

Provided is a method of a method of preparing a Rosa laevigata fruit extract which regulates CD36, ApoA1, and SRB1, including extracting the fruit of Rosa laevigata using water, alcohols, or mixtures of water and alcohols as solvents. Also provided is a method of regulating CD36, ApoA1, and SRB1, including administering to a subject a composition containing an effective amount of the Rosa laevigata fruit extract. By suppressing the gene expression of CD36 and enhancing the gene expression of ApoA1 and SRB1, the Rosa laevigata fruit extract may be used to regulate lipid metabolism and reduce liver lipid accumulation and blood lipid levels.

The present invention provides a method to prepare polysaccharides from Ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.

The invention provides application of zoledronic acid in preparation of drugs for treating fatty liver diseases. The fatty liver diseases include fatty liver diseases caused by food-borne and hereditary factors, especially non-alcoholic fatty liver diseases. According to the application, the zoledronic acid can be used for effectively treating the liver diseases and relieving liver lipid accumulation and fatty degeneration, has remarkable relief effect on the non-alcoholic fatty liver diseases and can reduce the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in blood, so that a new way for treating the fatty liver diseases and liver function damage is open up, a new indication is provided for clinical application of the zoledronic acid, and the potential and promising application prospect is created for the zoledronic acid in liver disease treatment.

The invention discloses a function and application of a (pro) resin receptor [(pro) resin receptor, (P) RR] inhibitor in nonalcoholic fatty livers and fat diseases. Under the background of C57 mice, (P) RR liver specificity knock-out/know-down mice are used as experimental objects, according to a fat mouse model which is induced through high-fat feed, and it is proved through a result that the size of the liver (P) RR knock-out mice is remarkably small, and the fat tissue in the mouse bodies is remarkably reduced; after the mice are fed with the high-fat feed, the increase amplitude of the weight of the mice is low, fat is not generated, the blood glucose content is low, through results of oil red dyeing, liver lipid measurement and the like, it is explained that the liver function of theliver (pro) resin receptor knock-out mice is remarkably better than that of contrasted fatty mice, the fatty liver lesion of the mice is remarkably improved, the stored lipid is remarkably reduced, and the blood glucose content is lowered. Therefore, (P) RR can be used as a medicine target of screening treatment of type-II diabetes, nonalcoholic fatty livers and fat diseases, and the inhibitor of(P) RR can be applied to preparation of medicine for treating type-II diabetes, nonalcoholic fatty livers and fat diseases.

The invention belongs to the technical field of medicine healthcare, and discloses a traditional Chinese medicine composition for improving the insulin resistance syndrome and a compound preparation and application thereof. The traditional Chinese medicine composition is prepared from 15-20 g of radix adenophorae, 9-15 g of radix pueraiae, 12-18 g of radix ophiopogonis, 15-20 g of radix rehmanniaepraeparata, 9-15 g of fructus corni, 9-15 g of radices trichosanthis, 27-33 g of dendrobe, 12-18 g of Chinese yam, 15-20 g of radix rehmanniae recen, 12-18 g of radix pseudostellariae, 12-18 g of radix astragali, 15-20 g of fructus lycii, 12-18 g of fructus ligustri lucidi, 9-15 g of rhizoma atractylodis macrocephalae, 9-15 g of radix aucklandiae, 12-18 g of rhizoma anemarrhenae, 9-15 g of radixsalviae miltiorrhizae and 9-15 g of radix scutellariae. The traditional Chinese medicine composition can remarkably reduce the weight, blood fat, serum insulin level of a II-type diabetes rat and improve the As index and insulin tolerance, remarkably reduces the ectopic accumulation of liver lipid of the II-type diabetes rat and promotes the function restoration of islet cells.

The invention provides application of CPT-II in the malignant transformation process induced by fat accumulation of liver cells. The application comprises the following steps of animal grouping, model preparing, blood enzymology and lipid detecting, liver cell fat staining, liver tissue protein preparing and concentration determining, quantitative analysis on the liver CPT-II concentration, pathologic histology examining, liver CPT-II immuohistochemistry staining and statistical analyzing. According to the application, by establishing fatty liver and liver mouse models and detecting changes of the CPT-II in the liver cell malignant transformation process, it is found that the CPT-II content in the fatty liver model is obviously lower than that of a normal control group, it shows that decrease of the liver cell CPT-II can be caused by liver lipid accumulation and fat degeneration, the CPT-II content of a liver cancer mouse model is significantly lower than that of the fatty liver model, and therefore the CPT-II content is in negative correlation with the liver cell malignancy grade. The liver CPT-II specific concentration and immunohistochemistry prove that the liver cells are progressively decreased in the canceration process, it shows that fat accumulation of the liver cells is aggravated due to low expression or dysfunction of the CPT-II, and a promoting effect is achieved on the liver cell maglignancy transformation process.

The invention discloses a traditional Chinese medicine composition for relieving nonalcoholic steatohepatitis and a preparation method and product thereof. The traditional Chinese medicine compositionis prepared from herba artemisiae scopariae, spreading hedyotis herbs, gardenia jasminoides ellis and herba taxilli at the ratio being 1:(0.8-1.5):(0.2-1.2):(0.2-1.2), the ingredients are water-extracted and then concentrated, and the traditional Chinese medicine composition is obtained. The traditional Chinese medicine composition can be made into a health care product or a medicine, and has animportant effect on alleviating the nonalcoholic steatohepatitis. Experiments prove that the traditional Chinese medicine composition can effectively relieve liver swelling, improve pathological changes of the liver, reduce liver lipid accumulation, lower the liver inflammatory factor level and effectively relieve NASH.

The invention relates to an improved mouse liver lipid droplet oil-red O staining method, and belongs to the technical field of lipid droplet detection. The method comprises preparing frozen slices bya tissue fixing step, a tissue dehydration step and a tissue section step. In the tissue fixing step, the fresh mouse liver is fixed for 3-10 days by adopting 10% formalin; and in the tissue dehydration step, the fixed mouse liver is soaked in a 15% sucrose solution for 24 hours, and then soaked in a 30% sucrose solution for 24 hours. According to the method, 10% formalin is firstly adopted to fix the mouse liver, and then 15% sucrose solution and 30% sucrose solution are adopted to perform gradient dehydration on the mouse liver, so that a staining result judgment can be determined more accurately.

The invention discloses functions and applications of RECS1 in the fatty liver and the diabetes mellitus, and belongs to the field of functions and applications of genes. An RECS1 gene knockout mouse and a wild type C57 mouse are used as experimental subjects, through a model of the fatty liver and the diabetes mellitus which are induced by high-fat diets, the result shows that compared with the wild type C57 mouse, glycometabolism of the RECS1 gene knockout mouse is disorderly, fatty liver lesion is severe, and lipid accumulation is remarkably increased. It explains that the RECS1 has the adjustment and control capacity for maintaining the steady state of glycometabolism and has the liver lipid removal capacity and fatty liver forming resistance. Thus, the functions of the RECS1 in the fatty liver and the diabetes mellitus are found and the functions are mainly reflected in the effects on alleviating fatty liver and diabetes mellitus. For the functions of the RECS1, the RECS1 can be used for preparing medicine for treating the fatty liver and the diabetes mellitus.